← All trials
NCT05184816
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 22, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jan 11, 2022
- Last posted
- Nov 1, 2022
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- Memorial Sloan-Kettering Cancer CenterOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.